| NCT04636268 | FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis | WITHDRAWN | PHASE3 | 2023-12 | 2025-03 | 2025-03 |
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | RECRUITING | PHASE3 | 2022-12-26 | 2026-06 | 2026-05 |
| NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-08-13 | 2025-07-17 | 2025-07-17 |
| NCT04847141 | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients | TERMINATED | PHASE3 | 2021-04-28 | 2021-12-27 | 2021-11-10 |
| NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) | TERMINATED | PHASE2 | 2021-01-29 | 2022-01-28 | 2021-12-13 |
| NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency | COMPLETED | PHASE4 | 2020-11-24 | 2022-07-25 | 2022-07-18 |
| NCT04480424 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) | COMPLETED | PHASE2 | 2020-09-17 | 2021-10-25 | 2021-08-25 |
| NCT04561115 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency | COMPLETED | PHASE3 | 2020-09-02 | 2022-03-28 | 2022-03-28 |
| NCT04495101 | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | COMPLETED | PHASE2 | 2020-07-29 | 2021-06-10 | 2021-04-26 |
| NCT04432324 | Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19) | COMPLETED | PHASE2 | 2020-06-02 | 2021-03-03 | 2021-03-03 |
| NCT04547127 | A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) | COMPLETED | PHASE2 | 2020-04-29 | 2021-02-04 | 2021-02-04 |
| NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency | WITHDRAWN | PHASE3 | 2019-12 | 2020-09 | 2020-09 |
| NCT03702920 | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% | TERMINATED | PHASE3 | 2019-02-21 | 2025-04-14 | 2025-04-14 |
| NCT03461406 | A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants | COMPLETED | PHASE3 | 2019-01-18 | 2022-05-20 | 2022-04-15 |
| NCT03451292 | Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites | COMPLETED | PHASE3 | 2018-07-24 | 2024-05-21 | 2024-05-21 |
| NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | TERMINATED | PHASE2 | 2018-01-03 | 2020-09-18 | 2020-09-18 |
| NCT03351933 | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) | COMPLETED | PHASE4 | 2017-10-31 | 2018-07-19 | 2018-04-27 |
| NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis | COMPLETED | PHASE2 | 2016-08-29 | 2019-08-15 | 2019-08-15 |
| NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) | COMPLETED | PHASE1, PHASE2 | 2016-07-29 | 2021-02-16 | 2021-02-16 |
| NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency | COMPLETED | PHASE1, PHASE2 | 2016-07-29 | 2017-03-15 | 2017-03-15 |
| NCT02281500 | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia | COMPLETED | PHASE1, PHASE2 | 2016-07-22 | 2019-11-11 | 2019-11-11 |
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency | ENROLLING_BY_INVITATION | PHASE3 | 2016-07 | 2029-02 | 2028-09 |
| NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency | COMPLETED | PHASE3 | 2016-06 | 2019-05-15 | 2019-05-15 |
| NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency | COMPLETED | PHASE3 | 2016-01 | 2017-12 | 2017-09 |
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | COMPLETED | PHASE2 | 2015-08 | 2018-01 | 2018-01 |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | COMPLETED | PHASE2 | 2015-06 | 2019-02 | 2019-02 |
| NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations | COMPLETED | PHASE3 | 2015-03 | 2018-04 | 2018-04 |
| NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency | COMPLETED | PHASE2, PHASE3 | 2014-10 | 2016-01 | 2016-01 |
| NCT02176863 | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome | TERMINATED | PHASE2, PHASE3 | 2014-09-23 | 2022-11-24 | 2022-11-24 |
| NCT02037555 | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass | COMPLETED | PHASE2 | 2014-06-26 | 2018-01-25 | 2018-01-25 |
| NCT02093221 | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus | TERMINATED | PHASE2 | 2014-03 | 2017-06 | 2017-01 |
| NCT02139657 | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) | COMPLETED | PHASE1 | 2014-03 | 2014-05 | 2014-05 |
| NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | RECRUITING | PHASE4 | 2013-12 | 2026-12 | 2025-04 |
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2013-11 | 2027-01 | 2026-08 |
| NCT01684410 | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2012-08 | 2013-10 | 2013-10 |
| NCT01465958 | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency | COMPLETED | PHASE4 | 2011-11 | 2013-10 | 2013-10 |
| NCT01201720 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" | COMPLETED | NA | 2011-03 | 2013-02 | 2013-01 |
| NCT01222117 | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion | COMPLETED | PHASE2 | 2010-12 | 2016-01 | 2015-12 |
| NCT01213043 | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency | COMPLETED | PHASE2 | 2010-11 | 2012-01 | 2012-01 |
| NCT01014975 | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients | COMPLETED | PHASE1, PHASE2 | 2009-11 | 2014-02 | 2013-11 |
| NCT00968695 | Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites. | COMPLETED | PHASE4 | 2009-07 | 2014-04 | 2014-04 |
| NCT00418483 | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion | COMPLETED | PHASE1 | 2007-03 | 2010-04 | 2010-04 |
| NCT00437671 | Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels | TERMINATED | PHASE4 | 2007-03 | 2007-09 | 2007-09 |
| NCT00389324 | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency | COMPLETED | PHASE2 | 2006-11 | 2008-08 | 2008-08 |
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency | COMPLETED | PHASE3 | 2006-06 | 2007-03 | 2007-03 |
| NCT00295061 | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults | COMPLETED | PHASE3 | 2006-05 | 2007-02 | 2007-02 |
| NCT00220740 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | COMPLETED | PHASE3 | 2004-04 | 2006-06 | 2006-06 |
| NCT00220805 | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration | COMPLETED | PHASE2 | 2004-01 | 2005-05 | 2005-05 |
| NCT00486837 | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients | COMPLETED | PHASE2 | 2003-12 | 2004-06 | 2004-06 |
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | COMPLETED | PHASE2 | 2003-12 | 2007-01 | 2007-01 |
| NCT00220727 | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP | COMPLETED | PHASE2 | 2003-07 | 2003-10 | 2003-10 |
| NCT00220779 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2002-12 | 2005-02 | 2005-02 |
| NCT00220766 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients | COMPLETED | PHASE3 | 2002-08 | 2004-03 | 2002-08 |